Bionime Corporation announced TFDA Approval for iFree Continuous Glucose Monitoring System Second-Class Medical Device License. The iFree Continuous Glucose Monitoring System (iFree CGM) is indicated for detecting glycemic trends and for the management of glucose in persons aged 18 to 80. It is designed to replace fingerstick blood glucose testing.

It also aids in detecting episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the iFree CGM results is based on the glucose trends and several potential readings over time.